Evidence map›Paper›PMID 35918701›Full record

ArticleLipids in health and disease2022

Current causes of death in familial hypercholesterolemia.

Victoria Marco-Benedí, Ana M Bea, Ana Cenarro, Estíbaliz Jarauta, Martín Laclaustra, Fernando Civeira

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Victoria Marco-BenedíHospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, Spain.
Ana M BeaHospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, Spain.
Ana CenarroUnidad de Lípidos, Hospital Universitario Miguel Servet, Avda Isabel La Católica 1-3, Zaragoza, 50009, Spain.
Estíbaliz JarautaHospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, Spain.
Martín Laclaustra *Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, Spain. martin.laclaustra@unizar.es.
Fernando Civeira *Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Zaragoza, Spain. civeira@unizar.es.
Hospital Universitario Miguel Servet · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESUniversidad de Zaragoza · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial hypercholesterolemia (FH) is a codominant autosomal disease characterized by high low-density lipoprotein cholesterol (LDLc) and a high risk of premature cardiovascular disease (CVD). The molecular bases have been well defined, and effective lipid lowering is possible. This analysis aimed to study the current major causes of death of genetically defined heterozygous familial hypercholesterolemia (heFH).

methodsA case‒control study was designed to analyse life-long mortality in a group of heFH and control families. Data from first-degree family members of cases and controls (nonconsanguineous cohabitants), including deceased relatives, were collected from a questionnaire and review of medical records. Mortality was compared among heFH patients, nonheFH patients, and nonconsanguineous family members.

resultsA total of 813 family members were analysed, 26.4% of whom were deceased. Among the deceased, the mean age of death was 69.3 years in heFH individuals, 73.5 years in nonheFH individuals, and 73.2 years in nonconsanguineous individuals, without significant differences. CVD was the cause of death in 59.7% of heFH individuals, 37.7% of nonheFH individuals, and 37.4% of nonconsanguineous individuals (P = 0.012). These differences were greater after restricting the analyses to parents. The hazard ratio of dying from CVD was 2.85 times higher (95% CI, (1.73-4.69) in heFH individuals than in individuals in the other two groups (non-FH and nonconsanguineous), who did not differ in their risk.

conclusionsCVD mortality in heFH individuals is lower and occurs later than that described in the last century but is still higher than that in non-FH individuals. This improved prognosis of CVD risk is not associated with changes in non-CVD mortality.

Indexed as

Cardiovascular DiseasesHypercholesterolemiaHyperlipoproteinemia Type IIAgedCase-Control StudiesCause of DeathCholesterol, LDLHumansCholesterol, LDLCardiovascular disease deathHeterozygous familial hypercholesterolemia phenotypeParental-offspring

Identifiers

PMID35918701
PMCPMC9344778
OpenAlexW4289523307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.